SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Data Sheet (Cat.No.T72953)

TargetMol

Zidesamtinib

Chemical Properties



CAS No. : 2739829-00-4

Formula: C22H22FN7O

Molecular Weight: 419.455

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	Zidesamtinib (NVL-520) is an orally active, selective, potent, and blood-brain-barrier-crossing inhibitor of ROS1 fusion and resistance mutations, inhibits ROS1 and ROS1 G2032R, and can be used in the study of non-small-cell lung cancer and solid tumors.
Targets(IC50)	ROS Kinase
In vivo	Female athymic Nude-Foxn1nu mice were subcutaneously implanted with tumor fragments from the CTG-0848 model. Zidesamtinib (0.04, 0.2, 1, 5, 15 mg/kg; oral gavage twice daily for 21 days) inhibited tumor volumes[1].

Solubility Information

Solubility	DMSO: 30 mg/mL (71.52 mM),Sonification is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.384 mL	11.9201 mL	23.8402 mL
5 mM	0.4768 mL	2.384 mL	4.768 mL
10 mM	0.2384 mL	1.192 mL	2.384 mL
50 mM	0.0477 mL	0.2384 mL	0.4768 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Drilon A, et al. NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations. Cancer Discov. 2022 Dec 13;CD-22-0968.

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481